Phase II evaluation of metoprine in patients with advanced colorectal carcinoma.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011739:Pyrimethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; C006308:metoprine; D011739:Pyrimethamine